HEPATOPROTECTIVE EFFECTS OF BROMOCRIPTINE ON LIVER MARKERS AND HISTOPATHOLOGICAL CHANGES IN DIABETES-INDUCED RATS
Main Article Content
Keywords
Type 2 Diabetes, alkaline phosphatase, Gamma GT, SGPT, Bromocriptine
Abstract
Background: Globally, diabetes is a highly heritable disease that causes considerable damage to vital organs, compromising the liver's function. However, liver dysfunction, as indicated by abnormal liver function markers, poses a significant challenge nowadays.
Objectives: Bromocriptine has been found to enhance insulin sensitivity, reduce insulin resistance, and exhibit potential in treating type 2 diabetes mellitus. The purpose of this study is to assess its effect on liver. In this study, effects on hepatic markers were examined i.e. the levels of bilirubin, alkaline phosphatase, Gamma GT and SGPT.
Study Design: Experimental.
Place and Duration: The study was conducted at Karachi University, Department of Pharmacology, from November 2022 to April 2023.
Methods: The invivo testing was done by taking the blood samples of normal and diabetic male rat and assessed the liver function markers compared to control diabetic group. Moreover, diabetic induced group caused substantial damage to liver architecture, which was positively reversed by bromocriptine. In conclusion, demonstrates potential in treating diabetes and protecting the liver from diabetes-induced damage
Conclusion: The studied concluded that pandanus have marked good antidiabetic activity and protecting the liver from diabetes
References
2. Honeycutt AA, Boyle JP, Broglio KR, Thompson TJ, Hoerger TJ, Geiss LS, et al. A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050. Health Care Manag Sci. 2003;6:155–64. doi: 10.1023/a:1024467522972.
3. Rathmann W, Giani G. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:2568–9. doi: 10.2337/diacare.27.10.2568
4. El–Serag *, James E. Everhart. Diabetes increases the risk of acute hepatic failure:Gastroenterology Volume 122, Issue 7, June 2002, Pages 1822-1828
5. André J. Scheen.Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update: Expert Opinion on Drug Metabolism & Toxicology Volume 19, 2023 - Issue 8
6. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009;31:2608-17
7. Barra C1,* , Costa A1 , Tavares G1 , Marques D1 , Rodrigues T1 , Seiça R1 , Conde SV2 , Matafome P1,3 , Letra L1,4. ffect of Bromocriptine in improving Non-alcoholic Fatty Liver Disease in obese animal model of Type 2 Diabetes:Journal of HepatologyVolume 45, Issue 3, September 2006, Pages 439-444
8. M. Davis , Zhengtong Pei , Michael A. Trush , Lawrence J. Cheskin , Carlo Contoreggi , Karen McCullough , Paul A. Watkins, Timothy H. Moran. Bromocriptine reduces steatosis in obese rodent models:Journal of Hepatology Volume 45, Issue 3, September 2006, Pages 439-444
9. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". J Pharmacol Exp Ther. 303 (2): 791–804.
10. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". J Pharmacol Exp Ther. 303 (2): 805–14.
11. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, et al. (June 2010). "The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells". Biochemical Pharmacology. 79 (12): 1827–36.
12. Luo S, Luo J, Cincotta AH: Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster. Chronobiol Int. 2000, 17 (2): 155-172. 10.1081/CBI-100101040.
13. Luo S, Meier AH, Cincotta AH: Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology. 1998, 68 (1): 1-10. 10.1159/000054344.
14. Bina KG, Cincotta AH: Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000, 71 (1): 68-78.
15. Hansen B, Shaffrir E, Cincotta AH. Hypothalamic role in the insulin resistance syndrome. In Insulin Resistance Syndrome. Hansen B, Shaffrir E, Eds. London, Taylor and Francis, 2002, p. 271–312
16. Linda Cloete .Diabetes mellitus: an overview of the types, symptoms, complications and management: Nurs Stand. 2022 Jan 5;37(1):61-66.
17. Barbara Fletcher , Meg Gulanick, Cindy Lamendola.Risk factors for type 2 diabetes mellitus: J Cardiovasc Nurs. 2002 Jan;16(2):17-23
18. H Flórez .Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations: Invest Clin. 1997 Mar;38(1):39-52
19. H Florez , H Valbuena, E Ryder, E Rincón, G Campos, S Castillo, J González, V Fernández, X Raleigh, M E Gómez.Dyslipidemia and hyperinsulinemia in normoglycemic-obese relatives of patients with non-insulin dependent diabetes mellitus : Invest Clin. 1995 Sep;36(3):131-47.
20. G M Reaven .Pathophysiology of insulin resistance in human disease: Physiol Re. 1995 Jul;75(3):473-86.
21. Cincotta AH, Meier AH, Cincotta Jr M: Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999, 8 (10): 1683-1707.
22. Chen, J., et al. (2015). Bromocriptine attenuates renal fibrosis in chronic kidney disease. American Journal of Nephrology, 41(2), 147-156.
23. Felicitas Lopez Vicchi , Guillermina Maria Luque , Belen Brie , Juan Patricio Nogueira , Isabel Garcia Tornadu , Damasia Becu-Villalobos . Dopaminergic drugs in type 2 diabetes and glucose homeostasis: Pharmacol Res. 2016 Jul:109:74-80.
24. Sarah N Framnes-DeBoer , Ellen Bakke 1, Suma Yalamanchili 2, Hannah Peterson, Darleen A Sandoval , Randy J Seeley 3, Deanna M Arble 1. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor :Am J Physiol Endocrinol Metab.2020 Jan 1;318(1):E62-E71.
25. Mitchell IM, Pollock JCS, Jam MPG (2015) Effects of dopamine on liver blood flow in children with congenital heart disease. Ann Thorac Surg 60:1741–1744
26. Rajeshwara Krishna Prasad Adluri 1, Arvind V Singh, Julian Skoyles, Adrian Robins, Anthony Hitch, Mya Baker, Ian Moore Mitchell. The effect of fenoldopam and dopexamine on hepatic blood flow and hepatic function following coronary artery bypass grafting with hypothermic cardiopulmonary bypass: Eur J Cardiothorac Surg.2009 Jun;35(6):988-94.
27. Cincotta, A. H., & Meier, A. H. (1999). Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care, 22(6), 1040-1043.
28. El-Sayed, E. M., et al. (2015). Hepatoprotective effects of bromocriptine against carbon tetrachloride-induced liver damage in rats. Journal f Pharmacy and Pharmacology, 67(8), 1086-1096.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Sonia Khan
Associate Professor, Department of Pharmacology, Al-Tibri Medical College, Karachi, Pakistan
Syed Moazzam Ali Shah
Consultant Diabetologist, Al Ibrahim Eye Hospital, Malir, Karachi, Pakistan
Shahid Maqbool Korai
Assistant Professor, Department of Anatomy, Al-Tibri Medical College, Karachi, Pakistan
Asma Shabbir
Associate Professor, Department of Pathology, Jinnah Sindh Medical University, Karachi, Pakistan
Syeda Amber Zaidi
Associate Professor, Department of Pharmacology, Hamdard College of Medicine and Dentistry, Hamdard University, Karachi, Pakistan
Syed Mohsin Turab
Professor, Department of Pharmacology, Hamdard College of Medicine and Dentistry, Hamdard University, Karachi, Pakistan
Marvi
Assistant Professor, Department of Pharmacy, University of Baluchistan, Quetta, Pakistan.